Paper Details

  1. Home
  2. Paper Details

Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.

Author: ChenKehui, FangWenfeng, HuangYan, ShiXinyi, SunJing, ZhangLi, ZhaoShen

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study highlights the need for new treatment options for patients with limited-stage small cell lung cancer (LS-SCLC). The standard therapy for LS-SCLC is platinum-based chemotherapy combined with thoracic radiotherapy, but most patients eventually experience disease progression.
Paper Details　
Original Abstract of the Article :
There is still a substantial need of more treatment options for patients with limited-stage small cell lung cancer (LS-SCLC). The standard therapy for LS-SCLC is platinum-based doublet chemotherapy administered concurrently with thoracic radiotherapy (cCRT). In China, sequential chemoradiotherapy (s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cllc.2023.06.009

データ提供：米国国立医学図書館（NLM）

Sugemalimab: A New Oasis in the Desert of Small Cell Lung Cancer

This study delves into the vast desert of small cell lung cancer (SCLC) research, exploring the potential of sugemalimab as a novel treatment option for this challenging disease. The study focuses on the use of sugemalimab as consolidation therapy in patients with limited-stage SCLC who have not progressed following standard chemotherapy and radiation treatment. The authors present a detailed rationale for a Phase II/III randomized clinical trial, highlighting the need for new treatment strategies to improve outcomes for patients with this aggressive form of cancer. This research offers hope for a new oasis in the desert of SCLC treatment, potentially improving survival rates and quality of life for patients.

A New Oasis for Small Cell Lung Cancer Treatment

The study presents a compelling case for exploring the potential of sugemalimab as a novel treatment option for small cell lung cancer. Like a desert traveler seeking a refreshing oasis, researchers are eager to explore this potential new avenue for combating this aggressive form of cancer. The proposed clinical trial offers a promising pathway for evaluating the effectiveness and safety of this novel therapy, potentially leading to significant improvements in treatment outcomes for patients with SCLC.

Navigating the Desert of Small Cell Lung Cancer

This research provides a beacon of hope in the challenging landscape of small cell lung cancer treatment. By exploring the potential of novel therapies like sugemalimab, clinicians can continue to navigate this complex desert, seeking innovative approaches to improve outcomes for patients. The study highlights the importance of ongoing research and clinical trials in developing new treatment strategies for this formidable foe.

Dr. Camel's Conclusion

This research offers a glimmer of hope in the desert of small cell lung cancer treatment. By exploring the potential of sugemalimab as a novel therapy, we can continue to navigate this challenging landscape, seeking new oases of effective treatment options. This study underscores the importance of ongoing research and clinical trials in finding solutions for those facing this formidable foe.

Date :
  1. Date Completed 2023-11-03
  2. Date Revised 2023-11-07
Further Info :

Pubmed ID

37442748

DOI: Digital Object Identifier

10.1016/j.cllc.2023.06.009

Related Literature

Article Analysis
・Effective treatment of lung cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.